Clinical Trials on VEGFR-TKI

Total 541 results

Fujian Cancer Hospital

Not yet recruiting

Almonertinib Plus Metronomic Oral Vinorelbine

NSCLC | EGFR | Third-generation TKI
Shenzhen People's Hospital

Unknown

Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC (AFLC)

NSCLC | Apatinib | EGFR-TKI

China
GenoSaber
Sun Yat-sen University; Shanghai Chest Hospital; Shanghai Pulmonary Hospital,...

Unknown

Human EGFR Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method)

Non Small Cell Lung Cancer | EGFR-TKI Resistant Mutation | EGFR-TKI Sensitizing Mutation
Sun Yat-sen University

Recruiting

A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

Non-small Cell Lung Cancer (NSCLC) | EGFR-TKI Resistant Mutation | EGFR-TKI Sensitizing Mutation | Somatic Mutation | Germline Mutations

China
Fudan University

Recruiting

Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma

Carcinosarcoma | Sarcomatoid Carcinoma | PD-1 Immunotherapy | VEGFR-TKI

China
Sierra Oncology, Inc.

Terminated

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

EGFR Mutated EGFR TKI Naive Metastatic NSCLC

United States
Astellas Pharma Inc

Terminated

A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations

Japan
China Medical University Hospital

Not yet recruiting

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Non-small Cell Lung Cancer | EGFR Gene Mutation | EGFR-TKI Resistant Mutation
Second Xiangya Hospital of Central South University
The First Affiliated Hospital of Nanchang University; Xiangya Hospital of Central... and other collaborators

Recruiting

Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study) (PRECISE)

Lung Cancer, Non-small Cell | Circulating Tumor DNA | EGFR Gene Mutation | EGFR-TKI Resistant Mutation | Primary Resistance

China
Fifth Affiliated Hospital, Sun Yat-Sen University

Not yet recruiting

Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation (Neoafa)

Chemotherapy | Surgery | Non Small Cell Lung Cancer | EGFR Activating Mutation | EGFR TKI
Shanghai Cancer Hospital, China

Unknown

Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study

Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT

China
Tianjin Medical University Cancer Institute and...

Recruiting

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Non-small Cell Lung Cancer | EGFR Activating Mutation | EGFR-TKI Resistant Mutation | Cell Cycle Deregulation

China
Degan Lu
Wu Jieping Medical Foundation

Not yet recruiting

A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody

Lung Cancer | Anlotinib | TKI Resistance | EGFR Sensitive Mutation | Pianzumab
xuna
Nanfang Hospital of Southern Medical University; Sun Yat-Sen Memorial Hospital... and other collaborators

Withdrawn

Prophylactic HQP1351 Therapy Post-transplants on Leukemia After Allo-HSCT (Case-Only)

Prophylactic HQP1351 Therapy | Third Generation TKI

China
Sun Yat-sen University

Recruiting

A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors

China
Qingdao Central Hospital

Completed

Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)

EGFR-TKI Resistant Mutation

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML

CML, CML-CP,MMR,TKI

China
Yuankai Shi

Unknown

Chidamide With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
German Cancer Research Center

Completed

Reduction of Cancer Related Fatigue in Patients During TKI Therapy (RECAP)

All Tumor Entities Treated With TKI Therapy

Germany
Hangzhou Cancer Hospital

Unknown

RT Plus EGFR-TKI for Wild-type NSCLC

Non-small Cell Lung Cancer | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)

China
Chulalongkorn University

Recruiting

Separation Versus Integrated Approach in Combining ECMO With CRRT

AKI

Thailand
University of Iowa

Completed

The Impact of CRRT Modality on Filter Life

AKI

United States
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

EGFR Gene Mutation

China
Kaohsiung Medical University Chung-Ho Memorial...

Completed

The Comparisons of Effects of Core Stability Exercise and Tai Chi on Core Muscle Performances in Elderly

Tai Ji
Blueprint Medicines Corporation

Terminated

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Neoplasms | Respiratory Tract Diseases | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | Non Small Cell Lung... and other conditions

United States
Renibus Therapeutics, Inc.

Completed

Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing CABG and/or Cardiac Valve Surgery (START)

AKI

United States, Australia, Canada
Shanghai Henlius Biotech

Not yet recruiting

A Randomized, Single Intravenous Dose, Parallel Phase I Clinical Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX05 Vs. Erbitux® (Cetuximab) in Healthy Adult Male Chinese Subjects

EGFR Overexpression
Phramongkutklao College of Medicine and Hospital

Unknown

Protective Effects of Oral L-Arginine CI-AKI

Contrast Induced AKI

Thailand
Chulalongkorn University

Completed

Topical Bevacizumab for Preventing Recurrent Pterygium

Pterygium | Bevacizumab | VEGF | Anti-VEGF

Thailand
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC (effect)

EGFR Gene Mutation
Blueprint Medicines Corporation

Active, not recruiting

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | EGF-R Positive Non-Small Cell Lung... and other conditions

United States, Canada, Taiwan, Korea, Republic of, Singapore, Japan, United Kingdom, France, Netherlands, Spain
Force Therapeutics
OSI Orthopedics and Sports Medicine; Rehab 360 Knee Glider

Not yet recruiting

Does an Active Range of Motion Monitor Improve Outcomes/Decrease Cost for Patients Undergoing Total Knee Arthroplasty?

Total Knee Arthroplasty (TKA)
Fujian Cancer Hospital

Not yet recruiting

the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy

Non-small Cell Lung Cancer Confirmed by Histopathology or Cytology | The TNM (8th) Phase is IV | With EGFR Mutations | Meningeal Progression Occurred After Previous Platinum-containing Two-drug Chemotherapy and Third-generation EGFR-TKI Treatment | Male or Female | The Age of 18 Years Old or... and other conditions
Tianjin Medical University Second Hospital

Recruiting

Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors

Solid Tumor | EGFR Amplification

China
Sisli Hamidiye Etfal Training and Research Hospital

Completed

Lung Ultrasound in PD Patients (LUSiPD)

Peritoneal Dialysis | Hypervolemia | VEGF Overexpression

Turkey
Universitair Ziekenhuis Brussel
Merck Serono International SA

Unknown

Pregnancy Rates in IVF After Ovulation Triggering With Recombinant or Urinary Human Chorionic Gonadotrophin (HCG)

Pregnancy | Embryonic Development | VEGF

Belgium
Zhejiang Cancer Hospital

Unknown

Acquired Resistant Mechanism of the First-generation EGFR TKIs

Non-small Cell Lung Cancer | Aquired Resistance | EGFR TKIs

China
Sheng-Teng Huang

Completed

To Investigate the Metabolomics in the Subjects With Long Term Tai Chi Chuan Practice

Metabolomics | Tai Chi Chuan

Taiwan
Chinese PLA General Hospital

Recruiting

TGFβR-KO CAR-EGFR T Cells in Previously Treated Advanced EGFR-positive Solid Tumors

Solid Tumor, Adult | EGFR Overexpression

China
Chinese PLA General Hospital

Unknown

Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR) (CART-EGFR)

Advanced EGFR-positive Solid Tumors

China
Power Life Sciences Inc.

Not yet recruiting

Understanding Patient Engagement Trends in TBI Clinical Research

TBI

United States
Shanghai Henlius Biotech

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of HLX07 in nsqNSCLC Patients With High EGFR Expression

HLX07, nsqNSCLC, High EGFR Expression

China
AstraZeneca

Completed

ARTEMIS DIANE T790M (An Amino Acid Substitution at Position 790 in EGFR, From a Threonine (T) to a Methionine (M)) Mutation at Hospital Laboratories in Comparison With Central Laboratory

Locally Advanced or Metastatic EGFR(+) NSCLC Patients

China
AstraZeneca

Completed

A Retrospective, Non-interventional, Multicenter, Observational Chart Review Study to Explore the Clinical Benefits of Retreatment With TKI in the Real World. (SEQUENCE)

Locally Advanced or Metastatic EGFR Mutated NSCLC.

Taiwan
ImmunoGen, Inc.

Terminated

A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors

EGFR Positive Solid Tumors

United States
Shandong Cancer Hospital and Institute
AstraZeneca

Unknown

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Nonsmall Cell Lung Cancer | Brain Metastases | EGFR-TKI Resistant Mutation | AZD9291
China Medical University Hospital

Recruiting

Knee-Hip-Spine Harmony: The Relationship Between Sagittal Spinal Alignment in Total Hip/Knee Arthroplasty

Cases Who Received TKA/THA

Taiwan
Changchun Intellicrown Pharmaceutical Co. LTD
Covance

Recruiting

ZZ06 in Adult Patients With Advanced EGFR Positive Solid Tumor Malignancies

Advanced EGFR Positive Solid Tumor

United States, China
National Yang Ming University

Completed

the Effects of Individualized Tai Chi Training on Balance Control in Elderly

Tai Ji
Bristol-Myers Squibb

Completed

MAD Refractory: Solid Tumor QD w/o Break

HER2 or EGFR Expressing Advanced Solid Malignancies

Spain, France

Clinical Trials on VEGFR-TKI

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations